MAIA Biotechnology, Inc. (MAIA)
USD 1.45
(-1.03%)
USD 1.45
(-1.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -19.77 Million USD | -25.1% |
| 2022 | -15.8 Million USD | -18.97% |
| 2021 | -13.28 Million USD | -99.24% |
| 2020 | -6.66 Million USD | -2.7% |
| 2019 | -6.49 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -8.87 Million USD | -10.06% |
| 2024 Q1 | -8.06 Million USD | -28.94% |
| 2023 Q1 | -4.05 Million USD | 1.58% |
| 2023 FY | -19.77 Million USD | -25.1% |
| 2023 Q3 | -4.87 Million USD | -7.78% |
| 2023 Q4 | -6.25 Million USD | -28.32% |
| 2023 Q2 | -4.52 Million USD | -11.57% |
| 2022 Q2 | -3.16 Million USD | 6.33% |
| 2022 Q1 | -3.38 Million USD | -16.97% |
| 2022 FY | -15.8 Million USD | -18.97% |
| 2022 Q4 | -4.11 Million USD | 17.05% |
| 2022 Q3 | -4.96 Million USD | -56.69% |
| 2021 Q2 | -3.43 Million USD | -248.65% |
| 2021 FY | -13.28 Million USD | -99.24% |
| 2021 Q1 | -983.99 Thousand USD | 70.04% |
| 2021 Q4 | -2.89 Million USD | 44.33% |
| 2021 Q3 | -5.19 Million USD | -51.47% |
| 2020 Q4 | -3.28 Million USD | -348.14% |
| 2020 Q3 | -732.92 Thousand USD | 0.0% |
| 2020 FY | -6.66 Million USD | -2.7% |
| 2019 FY | -6.49 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 31.728% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -129.065% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 71.362% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 59.497% |
| Azitra, Inc. | -11.28 Million USD | -75.233% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -159.011% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -167.897% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 32.322% |
| CEL-SCI Corporation | -32.36 Million USD | 38.908% |
| iBio, Inc. | -24.9 Million USD | 20.613% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 7.973% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 13.814% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -30.281% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -105.113% |
| NanoViricides, Inc. | -8.29 Million USD | -138.396% |
| Oragenics, Inc. | -20.65 Million USD | 4.274% |
| BiomX Inc. | -26.16 Million USD | 24.441% |
| BiomX Inc. | -26.16 Million USD | 24.441% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 337.884% |
| Palatin Technologies, Inc. | -29.73 Million USD | 33.505% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 56.271% |
| Theriva Biologics, Inc. | -18.34 Million USD | -7.76% |